Status:
UNKNOWN
Role of Adrenomedullin in Leukemic Endosteal/Vascular Niches
Lead Sponsor:
Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The present study will be divided into 5 phases: 1. Collection of bone marrow and peripheral blood (PB) samples from AML patients at diagnosis; 2. Measurement of Midregional Proadrenomedullin (MR-pro...
Eligibility Criteria
Inclusion
- Patients with new diagnosis of primary or secondary AML.
- Participant is willing and able to give signed written informed consent according to ICH/EU/GCP and national local laws.
- Male or Female, aged \>18 years.
Exclusion
- Patients affected by concomitant cardiovascular disease , such as essential hypertension (any grade), chronic renal failure (creatinine\>1.5 mg/dL), heart failure (any NYHA class), and peripheral arterial occlusive diseases, or sepsis.
- Patients affected by HIV, B or C hepatitis.
Key Trial Info
Start Date :
June 9 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2024
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT04460963
Start Date
June 9 2021
End Date
June 1 2024
Last Update
November 28 2022
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Policlinico S. Orsola-Malpighi - Uoc Ematologia
Bologna, Italy
2
As Dell'Alto Adige, Ospedale Centrale Di Bolzano - Ematologia E Centro Trapianto Midollo Osseo
Bolzano, Italy
3
U.O. Oncoematologia IOV
Castelfranco Veneto, Italy
4
Ente Ecclesiastico Casa Sollievo Della Sofferenza - Ematologia
San Giovanni Rotondo, Italy